Technology like this could expand further to form better collaborations between pharma, payers and organized providers.
Management turnover has brought the opportunity to keep up the pressure.
Merck CEO Kenneth Frazier's exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.
Our goal is to make gender parity a priority, and to keep our spotlight trained on it.
Welcome to what may be the most comprehensive MM&M Agency Top 100 ever.
To be sure, anything borrowing from the well-known "Keep Calm" genre should not be construed as advice. The doctor is definitely not in.
Healthcare's collision with lower-cost genetic sequencing, mobile tech, AI, and consumerization will transform the trajectory of how we live for the next 10 years.
In the wake of MD Anderson's costly failure with IBM's Watson supercomputer, a Watson backlash brewing in biopharma may lead to a moment of reckoning in life sciences.
Despite budgets bouncing back from a decrease in 2015, big threats have appeared that may temper future plans, Iskowitz writes.
The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.